GlassScriptPhysician profile
Kevin Merle Windisch
NPI 1083617997
$941.28
in general payments reported to CMS, 2019-2025
19 companies · $666 in 2025
The $666 reported for 2025 was more than what 88% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
See the full distribution for Developmental - Behavioral Pediatrics
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.32 · 2021: $118 · 2022: $16.26 · 2023: $70.58 · 2024: $39.68 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $175.38 | 2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.43 | 2025 | Caplyta |
| Abbvie INC. | $90.37 | 2025 | |
| Supernus Pharmaceuticals, INC. | $85.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $75.48 | 2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $70.96 | 2025 | Auvelity |
| Corium, LLC | $55.04 | 2023-2025 | Azstarys |
| Alkermes, INC. | $46.53 | 2025 | Vivitrol |
| Viiv Healthcare Company | $34.76 | 2025 | Apretude |
| Tris Pharma INC | $31.60 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $26.04 | 2024 | |
| Janssen Pharmaceuticals, INC | $23.78 | 2025 | Invega Sustenna |
| Noven Therapeutics, LLC | $21.68 | 2023 | Secuado |
| Vertical Pharmaceuticals, LLC | $21.44 | 2025 | Relexxii |
| Glaxosmithkline, LLC. | $20.31 | 2023 | Bexsero |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $17.32 | 2021 | |
| Shire North American Group INC | $16.42 | 2019 | |
| Merck Sharp & Dohme LLC | $14.90 | 2019 | |
| Aytu Biopharma, INC. | $13.64 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Windisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.